GleamWall
中文EN

CERO CERO THERAPEUTICS HOLDINGS, INC.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1870404 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-259.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,130.6%
Debt / equity—
Current ratio0.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.61x
Accruals ratio157.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20232023-12-31
Income statement
Revenue——
R&D expense—$5.29M
SG&A expense—$2.39M
Operating income—-$7.68M
Interest expense—-$138,340
Pretax income-$19.92M-$2.44M
Income tax—$94,819
Net income-$19.92M-$7.29M
EPS (basic)—-1,248.64
EPS (diluted)—-1,248.64
Dividends declared per share10.37—
Weighted avg. shares (diluted)—5,838
Banking
Deposits$1.30M—
Balance sheet
Cash & equivalents$1.66M$1.60M
Current assets$2.73M$1.97M
PP&E, net$246,148$966,702
Total assets$3.64M$5.13M
Current liabilities$9.09M$3.51M
Total liabilities$9.09M$5.08M
Shareholders' equity-$5.45M-$42.06M
Shares outstanding—5,845
Cash flow statement
Operating cash flow-$16.10M-$1.52M
Investing cash flow—-$7.94M
Financing cash flow—-$32.58M
Stock-based compensation$1.10M$96,896
Dividends paid$127,144—
Share buybacks—$33.48M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.